The University of Chicago Header Logo

Connection

Aditya Juloori to Humans

Back to Details
This is a "connection" page, showing publications Aditya Juloori has written about Humans.
Aditya Juloori
Connection Strength
0.462
Humans
  1. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
    View in: PubMed
    Score: 0.028
  2. Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
    View in: PubMed
    Score: 0.028
  3. To Test and Preserve the Trachea. Int J Radiat Oncol Biol Phys. 2024 Aug 01; 119(5):1333.
    View in: PubMed
    Score: 0.028
  4. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1519-1530.
    View in: PubMed
    Score: 0.027
  5. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
    View in: PubMed
    Score: 0.025
  6. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
    View in: PubMed
    Score: 0.024
  7. Node Out, About It? Consideration of Adjuvant Treatment of Oral Tongue Cancer. Int J Radiat Oncol Biol Phys. 2022 Mar 15; 112(4):849.
    View in: PubMed
    Score: 0.024
  8. Beyond PACIFIC: Uncharted Waters. J Thorac Oncol. 2021 05; 16(5):715-718.
    View in: PubMed
    Score: 0.022
  9. Radiation Therapy for Cutaneous Malignancies of the Head and Neck. Otolaryngol Clin North Am. 2021 Apr; 54(2):307-327.
    View in: PubMed
    Score: 0.022
  10. Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the Hypopharynx: Long-term Outcomes and Toxicity. Anticancer Res. 2018 Jun; 38(6):3543-3549.
    View in: PubMed
    Score: 0.018
  11. Influence of preoperative radiation field on postoperative leak rates in esophageal cancer patients after trimodality therapy. J Thorac Oncol. 2014 Apr; 9(4):534-40.
    View in: PubMed
    Score: 0.014
  12. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025. J Natl Compr Canc Netw. 2025 Sep; 23(9):354-362.
    View in: PubMed
    Score: 0.008
  13. Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer. Clin Cancer Res. 2025 Aug 01; 31(15):3150-3159.
    View in: PubMed
    Score: 0.008
  14. Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
    View in: PubMed
    Score: 0.007
  15. Patient-specific modeling of radiation-induced lymphopenia for head and neck cancer. Med Phys. 2025 Jun; 52(6):3583-3594.
    View in: PubMed
    Score: 0.007
  16. Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas. Oral Oncol. 2025 Apr; 163:107207.
    View in: PubMed
    Score: 0.007
  17. NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025. J Natl Compr Canc Netw. 2025 02; 23(2):2-11.
    View in: PubMed
    Score: 0.007
  18. American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy. J Thorac Oncol. 2024 Dec; 19(12):1654-1667.
    View in: PubMed
    Score: 0.007
  19. Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society. J Thorac Oncol. 2024 Dec; 19(12):1640-1653.
    View in: PubMed
    Score: 0.007
  20. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
    View in: PubMed
    Score: 0.007
  21. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw. 2024 05; 22(4):249-274.
    View in: PubMed
    Score: 0.007
  22. Oncologic Safety of Close Margins in Patients With Low- to Intermediate-Grade Major Salivary Gland Carcinoma. JAMA Otolaryngol Head Neck Surg. 2024 02 01; 150(2):107-116.
    View in: PubMed
    Score: 0.007
  23. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
    View in: PubMed
    Score: 0.006
  24. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy. Adv Mater. 2022 Sep; 34(39):e2110588.
    View in: PubMed
    Score: 0.006
  25. Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
    View in: PubMed
    Score: 0.006
  26. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
    View in: PubMed
    Score: 0.006
  27. Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. JAMA Netw Open. 2022 04 01; 5(4):e227240.
    View in: PubMed
    Score: 0.006
  28. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
    View in: PubMed
    Score: 0.006
  29. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
    View in: PubMed
    Score: 0.006
  30. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.006
  31. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.006
  32. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study. Am J Clin Oncol. 2020 07; 43(7):469-476.
    View in: PubMed
    Score: 0.005
  33. Salvage Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Primary Surgical Resection of Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 05; 22(3):e360-e365.
    View in: PubMed
    Score: 0.005
  34. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro Oncol. 2019 08 05; 21(8):1060-1068.
    View in: PubMed
    Score: 0.005
  35. Long-term complications and reconstruction failures in previously radiated breast cancer patients receiving salvage mastectomy with autologous reconstruction or tissue expander/implant-based reconstruction. Breast J. 2019 11; 25(6):1071-1078.
    View in: PubMed
    Score: 0.005
  36. Long-Term Outcomes After Autologous or Tissue Expander/Implant-Based Breast Reconstruction and Postmastectomy Radiation for Breast Cancer. Pract Radiat Oncol. 2019 Nov; 9(6):e497-e505.
    View in: PubMed
    Score: 0.005
  37. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. J Neurosurg. 2020 02 01; 132(2):503-511.
    View in: PubMed
    Score: 0.005
  38. Selectively sparing the submandibular gland when level Ib lymph nodes are included in the radiation target volume: An initial safety analysis of a novel planning objective. Oral Oncol. 2019 02; 89:79-83.
    View in: PubMed
    Score: 0.005
  39. Five-year outcomes of sparing level IB in node-positive, human papillomavirus-associated oropharyngeal carcinoma: A safety and efficacy analysis. Oral Oncol. 2019 02; 89:66-71.
    View in: PubMed
    Score: 0.005
  40. Factors Associated With Acute and Chronic Wound Complications in Patients With Soft Tissue Sarcoma With Long-term Follow-up. Am J Clin Oncol. 2018 10; 41(10):1019-1023.
    View in: PubMed
    Score: 0.005
  41. Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):413-419.e1.
    View in: PubMed
    Score: 0.005
  42. Local control for clinical stage I non-small cell lung cancer treated with 5-fraction stereotactic body radiation therapy is not associated with treatment schedule. Pract Radiat Oncol. 2018 Nov - Dec; 8(6):404-413.
    View in: PubMed
    Score: 0.005
  43. The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. J Neurooncol. 2017 Jun; 133(2):357-368.
    View in: PubMed
    Score: 0.004
  44. American Brachytherapy Society consensus statement for soft tissue sarcoma brachytherapy. Brachytherapy. 2017 May - Jun; 16(3):466-489.
    View in: PubMed
    Score: 0.004
  45. Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer. Pract Radiat Oncol. 2015 Jul-Aug; 5(4):e383-91.
    View in: PubMed
    Score: 0.004
  46. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):139-47.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.